API

A steroid is a type of organic compound that contains...

read more...

Pharma Intermediate

Pharmaceuticals refer to the drugs and medicines...

read more...

Speciality Chemicals

Specialty chemicals are those chemicals which is produced...

read more...

Products Under Devp.

New Products Under Development In response...

read more...

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2010
(Rs. In Lacs except per share data)
Particulars Quarter ended Quarter ended Nine Months Ended Nine Months Ended Year ended
30th Sept 2010 30th Sept 2009 30th Sept 2010 30th Sept 2009 31st Mar 2010
1. Gross Sales / Income from operations 11,444 12,601 23,659 24,437 49,695
Less : Excise Duty & Sales Tax 605 633 1,315 1,270 2,553

(a)
(Net) Sales / Income from operations
10,839 11,968 22,344 23,167 47,142
(b) Other Operating Income
-
-
-
-
-
2. Expenditure
(a)
(Increase)/ Decrease in stock in trade & WIP
(838) (323) (1,264) (104) 376
(b) Consumption of raw materials. 6,387 6,321 12,355 11,855 23,179
(c) Purchase of Traded Goods 1,721 2,025 3,951 3,755 8,202
(d) Employees cost 401 346 805 667 1,362
(e) Depreciation 377 334 738 662 1,352
(f) Other expenditure 1,739 1,726 3,547 3,160 6,859
(g) Total Expenditure 9,787 10,429 20,132 19,995 41,330
3.
Profit from Operations before Other Income,
1,051 1,539 2,212 3,173 5,811
Interest & Exceptional Item
4. Other Income 4 29 5 31 45
5.
Profit before Interest & Exceptional Items
1,055 1,568 2,217 3,204 5,856
6. Interest 288 409 562 832 1474
7.
Profit after Interest but before Exceptional Items
767 1,159 1,655 2,372 4,382
8. Exceptional Items - - - - -
9.
Profit from Ordinary Activities before Tax
767 1,159 1,655 2,372 4,382
10. Tax Expenses (Includes) 249 482 540 962 1,772
Provision for Taxation 179 414 402 827 1,502
Provision for Deffered Taxation 70 68 138 135 270
11.
Net profit from ordinary Activities after Tax
518 677 1,116 1,410 2,610
12.
Extraordinay Item (net of tax expenses )
- - - - -
13. Net Profit for the period 518 677 1,116 1,410 2,610
14.
Paid-up Equity Share Capital of Rs.10/- each.
1,211 1,171 1,211 1,171 1,211
15.
Reserves & Surplus (excluding revaluation reserves)
- - - -
12,898
16. Basic E P S(in Rs.) 4.28 5.79 9.21 12.04 22.08
17. Public shareholding
-Number of Shares 5827828 5864219 5827828 5864219 6051226
-Percentage of Total Shareholding 48.13 50.08 48.13 50.08 49.97
18. Promoters & Promoter Group
Shareholding
(a) Pledged/Encumbered
-Number of Shares NIL NIL NIL NIL NIL
-Percentage of shares( as a percentage of the total shareholding of promoter and promoter group) NIL NIL NIL NIL NIL
-Percentage of shares( as a percentage of total sharecapital of the Company) NIL NIL NIL NIL NIL
(b) Non-encumbered
-Number of Shares 6280722
5844331
6280722
5844331
6057324
-Percentage of shares( as a percentage of the total shareholding of promoter and promoter group) 100
100
100
100
100
-Percentage of shares( as a percentage of total sharecapital of the Company) 51.87
49.92
51.87
49.92
50.03

Notes :

1. The above results, reviewed by the Audit Committee, have been taken on record by the Board of Directors at their meeting held on 29th October, 2010

2. Company is operating as a Single Segment Company, engaged in pharmaceuticals business hence, the disclosure requirement as per AS - 17 'Segment Reporting' is not attracted.

3. The figures of the previous periods have been regrouped and rearranged wherever necessary.

4. Number of Investors complaints (i) pending at the begaining of quarter 1 (ii) received during the quarter : 7 (Iii) redressed : 7 (iv) pending at the end of the quarter : 1.

5. Financial results have been affected on account of shut down of Ciprofloxacin & Enrofloxacin plants for about 1 & half months for expansion. These plants are now operational. Metronidazole plant at sarigam has been operational at 50% capacity due to upgradation of treatment facility.

6. Statement of Assets and Liabiliites as on 30.09.2010 is annexed .

For and on behalf of the Board

FOR AARTI DRUGS LIMITED

Harshit M Savla
(Jt. Managing Director)

Place : Mumbai

Date : 29th October, 2010

 

Resource Download

Annual Report
Click here to download
annual report
Investor Presentation
Click here to download
Presentation

Copyright © 2010 Aarti Drugs Ltd. All Rights Reserved
Website Developed by : Sri Hema Infotech